image
Healthcare - Medical - Devices - NASDAQ - US
$ 18.09
-1.84 %
$ 796 M
Market Cap
-54.82
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AXGN stock under the worst case scenario is HIDDEN Compared to the current market price of 18.1 USD, AxoGen, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AXGN stock under the base case scenario is HIDDEN Compared to the current market price of 18.1 USD, AxoGen, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AXGN stock under the best case scenario is HIDDEN Compared to the current market price of 18.1 USD, AxoGen, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
159 M REVENUE
14.74%
-21.5 M OPERATING INCOME
27.75%
-21.7 M NET INCOME
24.98%
-5.72 M OPERATING CASH FLOW
64.42%
19.3 M INVESTING CASH FLOW
701.66%
1.95 M FINANCING CASH FLOW
8.92%
48.6 M REVENUE
1.53%
-316 K OPERATING INCOME
26.17%
-1.86 M NET INCOME
3.28%
3.9 M OPERATING CASH FLOW
-6.34%
-5 M INVESTING CASH FLOW
-305.52%
572 K FINANCING CASH FLOW
5.15%
Balance Sheet AxoGen, Inc.
image
Current Assets 88 M
Cash & Short-Term Investments 31 M
Receivables 25.1 M
Other Current Assets 31.8 M
Non-Current Assets 109 M
Long-Term Investments 0
PP&E 104 M
Other Non-Current Assets 4.53 M
Current Liabilities 30.4 M
Accounts Payable 11.8 M
Short-Term Debt 1.55 M
Other Current Liabilities 17.1 M
Non-Current Liabilities 70.7 M
Long-Term Debt 67.7 M
Other Non-Current Liabilities 2.99 M
EFFICIENCY
Earnings Waterfall AxoGen, Inc.
image
Revenue 159 M
Cost Of Revenue 31.1 M
Gross Profit 128 M
Operating Expenses 149 M
Operating Income -21.5 M
Other Expenses 254 K
Net Income -21.7 M
RATIOS
80.42% GROSS MARGIN
80.42%
-13.50% OPERATING MARGIN
-13.50%
-13.66% NET MARGIN
-13.66%
-22.70% ROE
-22.70%
-11.03% ROA
-11.03%
-15.09% ROIC
-15.09%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AxoGen, Inc.
image
Net Income -21.7 M
Depreciation & Amortization 5.55 M
Capital Expenditures -14.9 M
Stock-Based Compensation 14.4 M
Change in Working Capital -4.39 M
Others -3.97 M
Free Cash Flow -20.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AxoGen, Inc.
image
AXGN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership AxoGen, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
981 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
10 months ago
Mar 21, 2024
Sell 24.3 K USD
Zaderej Karen L.
CEO
- 3166
7.68 USD
10 months ago
Mar 21, 2024
Sell 23.7 K USD
Zaderej Karen L.
CEO
- 3086
7.68 USD
10 months ago
Mar 21, 2024
Sell 254 K USD
Zaderej Karen L.
CEO
- 33028
7.68 USD
10 months ago
Mar 21, 2024
Sell 24.1 K USD
DeVinney Erick Wayne
Chief Innovation Officer
- 3141
7.68 USD
10 months ago
Mar 21, 2024
Sell 5.54 K USD
DeVinney Erick Wayne
Chief Innovation Officer
- 721
7.68 USD
10 months ago
Mar 21, 2024
Sell 5.5 K USD
DeVinney Erick Wayne
Chief Innovation Officer
- 716
7.68 USD
10 months ago
Mar 21, 2024
Sell 4.68 K USD
Scopelianos Angelo
Chief R&D Officer
- 610
7.68 USD
10 months ago
Mar 21, 2024
Sell 7.83 K USD
Scopelianos Angelo
Chief R&D Officer
- 1020
7.68 USD
10 months ago
Mar 21, 2024
Sell 40.3 K USD
Scopelianos Angelo
Chief R&D Officer
- 5251
7.68 USD
10 months ago
Mar 21, 2024
Sell 35.3 K USD
Donovan Michael Patrick
VP Operations
- 4596
7.68 USD
10 months ago
Mar 21, 2024
Sell 5.54 K USD
Donovan Michael Patrick
VP Operations
- 721
7.68 USD
10 months ago
Mar 21, 2024
Sell 5.5 K USD
Donovan Michael Patrick
VP Operations
- 716
7.68 USD
10 months ago
Mar 07, 2024
Sell 320 K USD
Donovan Michael Patrick
VP Operations
- 36310
8.81 USD
10 months ago
Mar 07, 2024
Sell 225 K USD
Freitag Gregory Gene
Director
- 25000
9 USD
1 year ago
Dec 11, 2023
Sell 10.6 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 1410
7.52 USD
1 year ago
Dec 11, 2023
Sell 23.4 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 3120
7.51 USD
1 year ago
Dec 11, 2023
Sell 59.8 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 7970
7.5 USD
1 year ago
Sep 06, 2023
Bought 62.2 K USD
Wendell Amy McBride
Director
+ 10000
6.224 USD
1 year ago
Aug 23, 2023
Bought 65.6 K USD
Burke William P. Mr.
Director
+ 10000
6.56 USD
1 year ago
Aug 16, 2023
Bought 61.1 K USD
NEELS GUIDO J
Director
+ 10000
6.11 USD
1 year ago
Jun 01, 2023
Sell 108 K USD
Freitag Gregory Gene
Director
- 12500
8.65 USD
1 year ago
Jun 01, 2023
Sell 258 K USD
Freitag Gregory Gene
Director
- 29480
8.74 USD
1 year ago
May 23, 2023
Sell 25.9 K USD
Freitag Gregory Gene
Director
- 2828
9.17 USD
1 year ago
May 23, 2023
Sell 43 K USD
Freitag Gregory Gene
Director
- 4640
9.26 USD
1 year ago
Feb 01, 2023
Sell 136 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 14550
9.36 USD
1 year ago
Jan 31, 2023
Sell 137 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 14320
9.55 USD
1 year ago
Jan 30, 2023
Sell 137 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 14111
9.69 USD
1 year ago
Jan 27, 2023
Sell 213 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 20940
10.16 USD
2 years ago
Nov 16, 2022
Sell 127 K USD
MARIANI PETER J
EVP & Chief Financial Officer
- 10649
11.88 USD
2 years ago
Nov 14, 2022
Sell 166 K USD
Freitag Gregory Gene
Director
- 13000
12.74 USD
2 years ago
Nov 08, 2022
Sell 162 K USD
Freitag Gregory Gene
Director
- 13000
12.5 USD
2 years ago
Aug 10, 2022
Sell 86.2 K USD
Freitag Gregory Gene
director:
- 8886
9.696 USD
2 years ago
Aug 04, 2022
Sell 255 K USD
Freitag Gregory Gene
Director
- 24000
10.64 USD
2 years ago
Aug 04, 2022
Sell 135 K USD
Freitag Gregory Gene
director:
- 13046
10.37 USD
3 years ago
Aug 06, 2021
Sell 272 K USD
Zaderej Karen L.
CEO
- 14756
18.4 USD
3 years ago
Aug 06, 2021
Sell 24.1 K USD
Zaderej Karen L.
CEO
- 1259
19.18 USD
3 years ago
Aug 06, 2021
Sell 422 K USD
Zaderej Karen L.
CEO
- 22902
18.41 USD
3 years ago
Aug 06, 2021
Sell 39.9 K USD
Zaderej Karen L.
CEO
- 2083
19.16 USD
3 years ago
Jul 21, 2021
Sell 38.8 K USD
Donovan Michael Patrick
VP Operations
- 1935
20.04 USD
3 years ago
Jun 04, 2021
Sell 50 K USD
MARTINEZ MARIA D.
Chief Human Resources Officer
- 2652
18.86 USD
3 years ago
Feb 25, 2021
Sell 529 K USD
Freitag Gregory Gene
Director
- 24000
22.06 USD
3 years ago
Feb 18, 2021
Sell 34.6 K USD
Donovan Michael Patrick
VP Operations
- 1808
19.15 USD
4 years ago
Jan 08, 2021
Sell 1.3 M USD
Zaderej Karen L.
CEO
- 65000
20 USD
4 years ago
Dec 30, 2020
Sell 30.3 K USD
Donovan Michael Patrick
VP Operations
- 1733
17.48 USD
4 years ago
Dec 29, 2020
Sell 6.61 K USD
DeVinney Erick Wayne
VP, Clinical&Translational Sc
- 371
17.81 USD
4 years ago
Dec 29, 2020
Sell 10.1 K USD
Donovan Michael Patrick
VP Operations
- 567
17.81 USD
4 years ago
Dec 29, 2020
Sell 16.3 K USD
Freitag Gregory Gene
Director
- 916
17.81 USD
4 years ago
Dec 29, 2020
Sell 23 K USD
MARIANI PETER J
Chief Financial Officer
- 1293
17.81 USD
4 years ago
Dec 29, 2020
Sell 10.1 K USD
Scopelianos Angelo
VP Research & Development
- 567
17.81 USD
4 years ago
Dec 29, 2020
Sell 62.3 K USD
Zaderej Karen L.
CEO
- 3500
17.81 USD
4 years ago
Dec 29, 2020
Sell 10.1 K USD
Friedman Mark Louis
VP,Regulatory & Quality
- 567
17.81 USD
4 years ago
Dec 29, 2020
Sell 10.1 K USD
MARTINEZ MARIA D.
Chief Human Resources Officer
- 567
17.81 USD
4 years ago
Dec 29, 2020
Sell 11.6 K USD
Billet Isabelle
Chief Strategy and BD Officer
- 649
17.81 USD
4 years ago
Dec 22, 2020
Sell 4.8 K USD
Donovan Michael Patrick
VP Operations
- 279
17.19 USD
4 years ago
Dec 21, 2020
Sell 20.9 K USD
Zaderej Karen L.
CEO
- 1275
16.42 USD
4 years ago
Dec 21, 2020
Sell 2.41 K USD
DeVinney Erick Wayne
VP, Clinical&Translational Sc
- 147
16.42 USD
4 years ago
Dec 21, 2020
Sell 6.22 K USD
Freitag Gregory Gene
Director
- 379
16.42 USD
4 years ago
Dec 21, 2020
Sell 1.58 K USD
Donovan Michael Patrick
VP Operations
- 96
16.42 USD
4 years ago
Dec 21, 2020
Sell 7.9 K USD
MARIANI PETER J
Chief Financial Officer
- 481
16.42 USD
4 years ago
Dec 21, 2020
Sell 1.58 K USD
Friedman Mark Louis
VP,Regulatory & Quality
- 96
16.42 USD
4 years ago
Nov 09, 2020
Sell 264 K USD
Donovan Michael Patrick
VP Operations
- 17617
15 USD
4 years ago
Nov 09, 2020
Sell 203 K USD
Zaderej Karen L.
CEO
- 14000
14.53 USD
4 years ago
Oct 30, 2020
Sell 745 K USD
MARIANI PETER J
Chief Financial Officer
- 60000
12.412 USD
4 years ago
Oct 30, 2020
Sell 13.5 K USD
MARIANI PETER J
Chief Financial Officer
- 1084
12.41 USD
4 years ago
Oct 30, 2020
Sell 160 K USD
MARIANI PETER J
Chief Financial Officer
- 12854
12.41 USD
4 years ago
Oct 30, 2020
Sell 21.7 K USD
MARIANI PETER J
Chief Financial Officer
- 1745
12.414 USD
5 years ago
Aug 12, 2019
Bought 200 K USD
Blackford Quentin S.
Director
+ 14170
14.1 USD
5 years ago
Aug 09, 2019
Bought 2.61 K USD
Blackford Quentin S.
Director
+ 200
13.07 USD
5 years ago
Aug 09, 2019
Bought 15.3 K USD
Blackford Quentin S.
Director
+ 1165
13.1 USD
5 years ago
Aug 09, 2019
Bought 1.3 K USD
Gold Mark Stephen
Director
+ 100
13.04 USD
5 years ago
Aug 09, 2019
Bought 9.14 K USD
Gold Mark Stephen
Director
+ 700
13.05 USD
5 years ago
Aug 09, 2019
Bought 13.1 K USD
Gold Mark Stephen
Director
+ 1000
13.13 USD
5 years ago
Aug 09, 2019
Bought 1.3 K USD
Gold Mark Stephen
Director
+ 100
13.04 USD
5 years ago
Aug 09, 2019
Bought 1.3 K USD
Gold Mark Stephen
Director
+ 100
13.04 USD
5 years ago
Aug 09, 2019
Bought 26.2 K USD
Gold Mark Stephen
Director
+ 2000
13.106 USD
5 years ago
Aug 13, 2019
Bought 75.4 USD
Billet Isabelle
Chief Strategy and BD Officer
+ 5
15.079 USD
5 years ago
Aug 13, 2019
Bought 1.51 K USD
Billet Isabelle
Chief Strategy and BD Officer
+ 100
15.079 USD
5 years ago
Aug 13, 2019
Bought 1.51 K USD
Billet Isabelle
Chief Strategy and BD Officer
+ 100
15.079 USD
5 years ago
Aug 13, 2019
Bought 1.51 K USD
Billet Isabelle
Chief Strategy and BD Officer
+ 100
15.079 USD
5 years ago
Aug 13, 2019
Bought 1.51 K USD
Billet Isabelle
Chief Strategy and BD Officer
+ 100
15.12 USD
5 years ago
Aug 13, 2019
Bought 3.02 K USD
Billet Isabelle
Chief Strategy and BD Officer
+ 200
15.11 USD
5 years ago
Aug 13, 2019
Bought 1.51 K USD
Billet Isabelle
Chief Strategy and BD Officer
+ 100
15.12 USD
5 years ago
Aug 13, 2019
Bought 1.51 K USD
Billet Isabelle
Chief Strategy and BD Officer
+ 100
15.11 USD
5 years ago
Aug 13, 2019
Bought 1.51 K USD
Billet Isabelle
Chief Strategy and BD Officer
+ 100
15.12 USD
5 years ago
Aug 13, 2019
Bought 121 USD
Billet Isabelle
Chief Strategy and BD Officer
+ 8
15.12 USD
5 years ago
Aug 13, 2019
Bought 60.5 USD
Billet Isabelle
Chief Strategy and BD Officer
+ 4
15.12 USD
5 years ago
Aug 13, 2019
Bought 1.33 K USD
Billet Isabelle
Chief Strategy and BD Officer
+ 88
15.12 USD
5 years ago
Aug 13, 2019
Bought 70 K USD
Billet Isabelle
Chief Strategy and BD Officer
+ 4630
15.11 USD
5 years ago
Aug 14, 2019
Bought 30.3 K USD
MARTINEZ MARIA D.
Chief Human Resources Officer
+ 2000
15.13 USD
5 years ago
Aug 12, 2019
Bought 200 K USD
Blackford Quentin S.
Director
+ 14170
14.1 USD
5 years ago
Aug 09, 2019
Bought 2.61 K USD
Blackford Quentin S.
Director
+ 200
13.07 USD
5 years ago
Aug 09, 2019
Bought 15.3 K USD
Blackford Quentin S.
Director
+ 1165
13.1 USD
5 years ago
Aug 09, 2019
Bought 1.01 M USD
Zaderej Karen L.
CEO
+ 75000
13.499 USD
5 years ago
Jun 13, 2019
Sell 400 K USD
Donovan Michael Patrick
VP Operations
- 20000
20 USD
5 years ago
Jun 13, 2019
Bought 101 K USD
Wendell Amy McBride
Director
+ 5000
20.25 USD
5 years ago
May 13, 2019
Sell 453 K USD
Hansen David K
VP Finance & Treasurer
- 20000
22.63 USD
6 years ago
Nov 30, 2018
Sell 1.48 M USD
Freitag Gregory Gene
General Counsel
- 45000
33 USD
6 years ago
Nov 15, 2018
Sell 645 K USD
Freitag Gregory Gene
General Counsel
- 20000
32.25 USD
6 years ago
Nov 13, 2018
Sell 434 K USD
Zaderej Karen L.
CEO
- 13000
33.42 USD
6 years ago
Nov 14, 2018
Sell 395 K USD
Zaderej Karen L.
CEO
- 12000
32.93 USD
6 years ago
Aug 14, 2018
Bought 184 K USD
Wendell Amy McBride
Director
+ 5000
36.89 USD
6 years ago
May 16, 2018
Sell 435 K USD
MCCARREY SHAWN F
SVP Sales
- 10000
43.47 USD
6 years ago
Feb 21, 2018
Sell 1.63 M USD
Grooms Jamie Mark
Director
- 57406
28.4 USD
6 years ago
Feb 16, 2018
Sell 729 K USD
Grooms Jamie Mark
Director
- 26655
27.35 USD
6 years ago
Feb 20, 2018
Sell 1.03 M USD
Grooms Jamie Mark
Director
- 36740
27.9 USD
6 years ago
Feb 13, 2018
Sell 186 K USD
Grooms Jamie Mark
Director
- 7100
26.2 USD
6 years ago
Feb 14, 2018
Sell 880 K USD
Grooms Jamie Mark
Director
- 32936
26.72 USD
6 years ago
Feb 15, 2018
Sell 1.18 M USD
Grooms Jamie Mark
Director
- 43403
27.11 USD
6 years ago
Feb 13, 2018
Sell 83.9 K USD
Grooms Jamie Mark
Director
- 3200
26.22 USD
6 years ago
Feb 14, 2018
Sell 242 K USD
Grooms Jamie Mark
Director
- 9073
26.71 USD
6 years ago
Feb 13, 2018
Sell 186 K USD
Grooms Jamie Mark
VP, CFO
- 7100
26.2 USD
6 years ago
Feb 14, 2018
Sell 880 K USD
Grooms Jamie Mark
VP, CFO
- 32936
26.72 USD
6 years ago
Feb 15, 2018
Sell 1.18 M USD
Grooms Jamie Mark
VP, CFO
- 43403
27.11 USD
6 years ago
Feb 13, 2018
Sell 83.9 K USD
Grooms Jamie Mark
VP, CFO
- 3200
26.22 USD
6 years ago
Feb 14, 2018
Sell 242 K USD
Grooms Jamie Mark
VP, CFO
- 9073
26.71 USD
7 years ago
Dec 11, 2017
Sell 575 K USD
Grooms Jamie Mark
Director
- 21820
26.35 USD
7 years ago
Dec 12, 2017
Sell 437 K USD
Grooms Jamie Mark
Director
- 16585
26.34 USD
7 years ago
Dec 06, 2017
Sell 558 K USD
Grooms Jamie Mark
Director
- 21290
26.22 USD
7 years ago
Dec 07, 2017
Sell 887 K USD
Grooms Jamie Mark
Director
- 33500
26.47 USD
7 years ago
Dec 08, 2017
Sell 839 K USD
Grooms Jamie Mark
Director
- 31805
26.37 USD
7 years ago
Dec 06, 2017
Sell 558 K USD
Grooms Jamie Mark
Director
- 21290
26.22 USD
7 years ago
Dec 07, 2017
Sell 827 K USD
Grooms Jamie Mark
Director
- 31200
26.5 USD
7 years ago
Dec 08, 2017
Sell 839 K USD
Grooms Jamie Mark
Director
- 31805
26.37 USD
7 years ago
Nov 20, 2017
Sell 22.7 M USD
Essex Woodlands Fund IX, L.P.
10 percent owner
- 1150000
19.74 USD
7 years ago
Nov 20, 2017
Sell 22.7 M USD
NEELS GUIDO J
Director
- 1150000
19.74 USD
7 years ago
Sep 11, 2017
Sell 291 K USD
Rudelius Robert James
Director
- 16143
18 USD
8 years ago
Oct 07, 2016
Bought 100 K USD
Wendell Amy McBride
Director
+ 13333
7.5 USD
8 years ago
Oct 07, 2016
Bought 15 K USD
Leach Kevin
Vice President Marketing
+ 2000
7.5 USD
8 years ago
Oct 07, 2016
Bought 25 K USD
MARIANI PETER J
Chief Financial Officer
+ 3333
7.5 USD
8 years ago
Oct 07, 2016
Bought 75 K USD
Zaderej Karen L.
CEO
+ 10000
7.5 USD
8 years ago
Oct 07, 2016
Bought 30 K USD
Engels John P
VP
+ 4000
7.5 USD
8 years ago
Aug 08, 2016
Sell 927 K USD
Mandato Joseph M
Director
- 107450
8.63 USD
8 years ago
Aug 09, 2016
Sell 350 K USD
Mandato Joseph M
Director
- 42168
8.3 USD
8 years ago
Jul 21, 2016
Sell 684 K USD
Flynn James E
10 percent owner
- 102136
6.7 USD
8 years ago
Jul 14, 2016
Sell 1.59 M USD
Flynn James E
10 percent owner
- 206090
7.7 USD
8 years ago
Jul 15, 2016
Sell 233 K USD
Flynn James E
10 percent owner
- 31788
7.32 USD
8 years ago
Jul 18, 2016
Sell 285 K USD
Flynn James E
10 percent owner
- 41425
6.87 USD
9 years ago
Nov 06, 2015
Sell 34.3 K USD
Gold Mark Stephen
Director
- 6013
5.7 USD
9 years ago
Sep 18, 2015
Sell 1.9 M USD
Flynn James E
10 percent owner
- 345000
5.5014 USD
9 years ago
Jun 03, 2015
Bought 20.2 K USD
Mandato Joseph M
Director
+ 6500
3.1 USD
9 years ago
Jun 02, 2015
Bought 308 USD
Johnston Lee Robert Jr
Chief Finacial Officer
+ 100
3.08 USD
9 years ago
Jun 02, 2015
Bought 614 USD
Johnston Lee Robert Jr
Chief Finacial Officer
+ 200
3.07 USD
9 years ago
Jun 02, 2015
Bought 14.1 K USD
Johnston Lee Robert Jr
Chief Finacial Officer
+ 4600
3.06 USD
9 years ago
Jun 02, 2015
Bought 305 USD
Johnston Lee Robert Jr
Chief Finacial Officer
+ 100
3.05 USD
9 years ago
May 27, 2015
Bought 622 USD
Zaderej Karen L.
Chief Executive Officer
+ 200
3.11 USD
9 years ago
May 27, 2015
Bought 1.55 K USD
Zaderej Karen L.
Chief Executive Officer
+ 500
3.1 USD
9 years ago
May 27, 2015
Bought 8.32 K USD
Zaderej Karen L.
Chief Executive Officer
+ 2625
3.17 USD
9 years ago
Apr 08, 2015
Sell 469 K USD
Flynn James E
10 percent owner
- 144385
3.25 USD
10 years ago
Dec 10, 2014
Sell 146 K USD
Mandato Joseph M
Director
- 47658
3.0575 USD
10 years ago
Dec 11, 2014
Sell 7.38 K USD
Mandato Joseph M
Director
- 2342
3.15 USD
10 years ago
Dec 10, 2014
Bought 30.6 K USD
Johnston Lee Robert Jr
Chief Financial Officer
+ 10000
3.06 USD
10 years ago
Aug 12, 2014
Bought 11.5 K USD
Gold Mark Stephen
Director
+ 5000
2.295 USD
10 years ago
Aug 12, 2014
Bought 22.9 K USD
Gold Mark Stephen
Director
+ 10000
2.29 USD
10 years ago
Aug 12, 2014
Bought 11.4 K USD
Gold Mark Stephen
Director
+ 5000
2.285 USD
10 years ago
Aug 08, 2014
Bought 25.4 K USD
Gold Mark Stephen
Director
+ 11000
2.31 USD
10 years ago
Jun 06, 2014
Bought 510 USD
Johnston Lee Robert Jr
Chief Financial Officer
+ 200
2.549 USD
10 years ago
Jun 06, 2014
Bought 4.33 K USD
Johnston Lee Robert Jr
Chief Financial Officer
+ 1700
2.545 USD
10 years ago
Jun 06, 2014
Bought 6.63 K USD
Johnston Lee Robert Jr
Chief Financial Officer
+ 2600
2.55 USD
10 years ago
Jun 06, 2014
Bought 513 USD
Johnston Lee Robert Jr
Chief Financial Officer
+ 200
2.565 USD
10 years ago
Jun 06, 2014
Bought 518 USD
Johnston Lee Robert Jr
Chief Financial Officer
+ 200
2.59 USD
10 years ago
Jun 06, 2014
Bought 13.3 K USD
Johnston Lee Robert Jr
Chief Financial Officer
+ 5100
2.6 USD
10 years ago
Jun 03, 2014
Bought 12.2 K USD
Zaderej Karen L.
Chief Executive Officer
+ 5000
2.43 USD
10 years ago
Jun 03, 2014
Bought 468 USD
Freitag Gregory Gene
CFO
+ 200
2.34 USD
10 years ago
Jun 02, 2014
Bought 12.2 K USD
Freitag Gregory Gene
CFO
+ 5000
2.45 USD
10 years ago
May 20, 2014
Bought 5.26 K USD
Schiaparelli Jill F
SVP, Bus. Strategy&Marketing
+ 2000
2.63 USD
10 years ago
May 12, 2014
Bought 13.5 K USD
Zaderej Karen L.
Chief Executive Officer
+ 5000
2.7 USD
10 years ago
May 07, 2014
Bought 3.87 K USD
Gold Mark Stephen
Director
+ 1487
2.6 USD
10 years ago
May 06, 2014
Bought 1.27 K USD
Gold Mark Stephen
Director
+ 490
2.6 USD
10 years ago
Mar 13, 2014
Bought 1.98 K USD
Zaderej Karen L.
Chief Executive Officer
+ 572
3.47 USD
10 years ago
Mar 13, 2014
Bought 3.25 K USD
Zaderej Karen L.
Chief Executive Officer
+ 928
3.5 USD
11 years ago
Aug 29, 2013
Bought 40.5 K USD
MCCARREY SHAWN F
SVP of Sales
+ 12625
3.21 USD
11 years ago
Aug 28, 2013
Bought 28.4 K USD
MCCARREY SHAWN F
SVP of Sales
+ 8875
3.2 USD
11 years ago
Aug 28, 2013
Bought 7.98 K USD
MCCARREY SHAWN F
SVP of Sales
+ 2500
3.19 USD
11 years ago
Aug 28, 2013
Bought 3.25 K USD
MCCARREY SHAWN F
SVP of Sales
+ 1000
3.25 USD
11 years ago
Aug 24, 2013
Bought 15 K USD
MCCARREY SHAWN F
SVP of Sales
+ 5000
3 USD
11 years ago
Aug 14, 2013
Bought 15 K USD
Schiaparelli Jill F
SVP, Bus. Strategy&Marketing
+ 5000
3 USD
11 years ago
Aug 14, 2013
Bought 200 K USD
Harper John Frederick
Director
+ 66666
3 USD
11 years ago
Aug 14, 2013
Bought 25 K USD
Zaderej Karen L.
Chief Executive Officer
+ 8334
3 USD
11 years ago
Aug 14, 2013
Bought 25 K USD
Freitag Gregory Gene
CFO
+ 8334
3 USD
12 years ago
Oct 01, 2012
Bought 312 K USD
Harper John Frederick
Director
+ 86557
3.61 USD
12 years ago
Dec 10, 2012
Bought 2.25 K USD
Zaderej Karen L.
Chief Executive Officer
+ 900
2.5 USD
12 years ago
Dec 04, 2012
Bought 5.1 K USD
Schiaparelli Jill F
SVP, Bus. Strategy&Marketing
+ 2000
2.55 USD
12 years ago
Nov 29, 2012
Bought 2.7 K USD
Schiaparelli Jill F
SVP, Bus. Strategy&Marketing
+ 1000
2.7 USD
12 years ago
Nov 20, 2012
Bought 269 USD
Zaderej Karen L.
Chief Executive Officer
+ 100
2.69 USD
12 years ago
Nov 15, 2012
Bought 2.5 K USD
Schiaparelli Jill F
SVP, Bus. Strategy&Marketing
+ 1000
2.5 USD
12 years ago
Nov 15, 2012
Bought 2.54 K USD
Schiaparelli Jill F
SVP, Bus. Strategy&Marketing
+ 1000
2.54 USD
12 years ago
Nov 14, 2012
Bought 2 K USD
Schiaparelli Jill F
SVP, Bus. Strategy&Marketing
+ 750
2.66 USD
13 years ago
Dec 30, 2011
Bought 22.4 K USD
Freitag Gregory Gene
CFO
+ 9318
2.4 USD
13 years ago
Nov 05, 2011
Bought 9.45 K USD
Rudelius Robert James
Director
+ 3500
2.7 USD
13 years ago
Nov 02, 2011
Bought 9.62 K USD
Rudelius Robert James
Director
+ 3500
2.75 USD
13 years ago
Nov 02, 2011
Bought 2.7 K USD
Rudelius Robert James
Director
+ 1000
2.7 USD
13 years ago
Nov 01, 2011
Bought 1.35 K USD
Rudelius Robert James
Director
+ 500
2.7 USD
13 years ago
Nov 22, 2011
Bought 17.6 K USD
Freitag Gregory Gene
CFO
+ 6000
2.94 USD
13 years ago
Nov 22, 2011
Bought 8.61 K USD
Freitag Gregory Gene
CFO
+ 3000
2.87 USD
13 years ago
Nov 21, 2011
Bought 8.64 K USD
Freitag Gregory Gene
CFO
+ 3000
2.88 USD
13 years ago
Nov 21, 2011
Bought 7.32 K USD
Freitag Gregory Gene
CFO
+ 2500
2.93 USD
13 years ago
Nov 21, 2011
Bought 1.43 K USD
Freitag Gregory Gene
CFO
+ 500
2.86 USD
13 years ago
Sep 28, 2011
Bought 36.2 K USD
Hopfenspirger Larry
10 percent owner
+ 20000
1.81 USD
7. News
Axogen: Well Placed To Capitalize Growth At Higher Multiples Axogen: Well Placed To Capitalize Growth At Higher Multiples seekingalpha.com - 1 week ago
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 3 weeks ago
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year. zacks.com - 1 month ago
All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% The mean of analysts' price targets for AxoGen (AXGN) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 1 month ago
Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript Axogen, Inc (NASDAQ:AXGN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer. seekingalpha.com - 2 months ago
AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 3 months ago
First September Gains in 5 Years? Buy 3 Breakout Stocks Now Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today. zacks.com - 3 months ago
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®. globenewswire.com - 4 months ago
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 4 months ago
What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 4 months ago
Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? The mean of analysts' price targets for AxoGen (AXGN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 4 months ago
8. Profile Summary

AxoGen, Inc. AXGN

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 796 M
Dividend Yield 0.00%
Description AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Contact 13631 Progress Boulevard, Alachua, FL, 32615 https://www.axogeninc.com
IPO Date Dec. 17, 1986
Employees 426
Officers Mr. Harold D. Tamayo Vice President of Finance & Investor Relations Dr. Ivica Ducic M.D., Ph.D. Chief Medical Officer Mr. Erick DeVinney Chief Innovation Officer Mr. Jens Schroeder Kemp Chief Marketing Officer Ms. Karen Zaderej Advisor Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A. Chief Financial Officer Mr. Marc A. Began Executive Vice President, General Counsel & Chief Compliance Officer Ms. Doris Quackenbush Vice President of Sales Mr. Todd Puckett Vice President of Operations